Clinical Outcomes of Coronavirus Disease 2019 in People Living With Human Immunodeficiency Virus in South Korea: A Nationwide Population‐Based Cohort Study

ABSTRACT Background We aimed to compare the epidemiological and clinical characteristics of coronavirus disease 2019 (COVID‐19) in people living with human immunodeficiency virus (HIV) (PLWH) with those in people living without HIV (PLWoH). Methods This nationwide descriptive epidemiological study was conducted in South Korea between January 2020 and February 2022. The National Health Insurance claim data, comprising the data of the entire Korean population, were collected through the Health Insurance Review and Assessment Service. Results Among 3,653,808 individuals who were diagnosed with COVID‐19, 1311 (0.04%) were PLWH. All PLWH received antiretroviral therapy, and 26.47% had more than one underlying disease other than HIV infection. The overall in‐hospital mortality rates of PLWH and PLWoH were 0.76% and 0.25%, respectively (P = 0.002). According to the Cox proportional hazard model, no significant difference was observed in the in‐hospital mortality rate (hazard ratio [HR]: 1.80, 95% confidence interval [CI]: 0.70–4.67) between the PLWH and PLWoH. However, progression to severe or critical COVID‐19 was more common in PLWH (HR: 2.70, 95% CI: 1.37–5.33). In PLWH diagnosed with COVID‐19, a multivariable Cox regression analysis found old age (≥ 60 years) (HR: 6.9, 95% CI: 2.57–18.56) and diabetes mellitus (HR: 5.13, 95% CI: 2.02–13.00) as the independent risk factors for severe or critical COVID‐19. Conclusions PLWH had a significantly higher risk of developing severe or critical COVID‐19 compared with PLWoH. Our findings suggest the need for implementing tailored strategies to decrease the impact of COVID‐19 on PLWH.